Three of the top 10 selling drugs in the U.S. face no competition in the country and will cost Americans an estimated further $167 billion before they are expected to do so, the New York-based Initiative for Medicines, Access & Knowledge (I-MAK) said in a report.
- Categories:
- FISM News